China’s Healthcare Landscape: Key Insights from the 2022 Statistical Communique
The National Health Commission (NHC) has released “China’s Healthcare Statistical Communique 2022,” providing a comprehensive...
Policy / Regulatory
Hainan Implements New Regulations for Import Drugs and Medical Devices in Medical Tourism Zone
The Hainan Medical Products Administration, in conjunction with Hainan’s Health Commission Bureau, has unveiled a...
NHSA Completes Expert Review for National Reimbursement Drug List Updates
The National Healthcare Security Administration (NHSA) has announced the completion of the expert review stage...
China’s National Health Commission Launches Three-Year Patient Safety Campaign
The National Health Commission has issued a notification to launch a special patient safety campaign...
Beijing Launches Comprehensive Plan to Eliminate Cervical Cancer by 2030
The Beijing Municipal Health Commission, in collaboration with the Beijing Municipal Medical Insurance Bureau and...
NHSA Issues Guidelines to Strengthen Medical Insurance Payment Management
The National Healthcare Security Administration (NHSA) has released a set of guiding opinions aimed at...
Beijing Joins Jiangxi’s Interferon Volume-Based Procurement Initiative
The Beijing Municipal Medical Insurance Bureau has announced its participation in the Jiangxi-led interferon inter-provincial...
NMPA and NHC Tighten Regulations on Etomidate and Modafinil
The National Medical Products Administration (NMPA) and the National Health Commission (NHC) have jointly issued...
Guangdong Medicine Exchange Announces Volume-Based Procurement for Medical Devices
The Guangdong Medicine Exchange has issued three notifications regarding the volume-based procurement (VBP) of medical...
Shanghai Boosts Community Healthcare with Enhanced Reimbursement and Services
Shanghai’s healthcare security administration has announced a comprehensive set of measures aimed at enhancing community...
Beijing Insurance Bureau Launches Pilot to Boost Access to NRDL Drugs
The Beijing Municipal Medical Insurance Bureau has announced the initiation of pilot work aimed at...
Beijing-Tianjin-Hebei Region Initiates Drug VBP with 37 Medicines, Including Biologics
The Beijing Municipal Medical Insurance Bureau has issued a notification to commence the drug volume-based...
Hunchun Port Designated as Medical Materials Import Port by NMPA and GAC
The National Medical Products Administration (NMPA) and the General Administration of Customs have jointly released...
CDE Introduces New Guidelines for Generic Drug Quality and Efficacy Consistency Evaluation
The Center for Drug Evaluation (CDE) has released a new set of Guidelines for “the...
EU Chamber of Commerce in China Releases Position Paper, Addresses Pharma and Healthcare
The EU Chamber of Commerce in China has released its bi-annual “European Business in China...
CDE Releases 74th Batch of Generic Reference Preparations with 58 New Specifications
The Center for Drug Evaluation (CDE) has released the 74th batch of chemical generic reference...
China’s NHC Expands Rare Disease List, Includes 21 Cancer Types
The National Health Commission (NHC) of China has released an updated national list of rare...
NHSA Clears Retagliptin and Ambroxol for National Reimbursement Drug List Inclusion
The National Healthcare Security Administration (NHSA) has completed a review of the National Reimbursement Drug...
China’s CDE Proposes Removal of Ambroxol Inhalation Solution and Four Other Drugs
The Center for Drug Evaluation has issued a notification concerning the Chemical Generic Drug Reference...
NMPA Drafts Quality Management Norms for Online Medical Device Sales
The National Medical Products Administration (NMPA) has issued the “Medical Device Online Sales Quality Management...